成都治疗血管瘤成都中医治疗静脉血栓的方法,成都治疗血糖足哪家医院便宜,成都老年{静脉炎}如何治疗,成都下肢静脉曲张的治疗要多少钱,成都治疗肝血管瘤的医院哪家好,成都治疗鲜红斑痣哪家好,成都下肢动脉硬化好治疗

The Supreme Court says Justice Ruth Bader Ginsburg has been discharged from a hospital in New York City and has returned home. The court says Ginsburg, 87, is doing well, two days after undergoing a minimally invasive procedure on Wednesday to “revise a bile duct stent” at Memorial Sloan Kettering Cancer Center. The stent had originally been placed last August, when Ginsburg was treated for a cancerous tumor on her pancreas. Ginsburg announced earlier this month that she is receiving chemotherapy for a recurrence of cancer.Stent revisions are common occurrences and the procedure, performed using endoscopy and medical imaging guidance, was done to minimize the risk of future infection, her doctors said, according to a statement.In May, Ginsburg was hospitalized for treatment for a benign gallbladder condition.Ginsburg has also beaten cancer four times after suffering from pancreatic cancer last year. 921

The school buildings in Evanston, Illinois, are still empty. But the district’s recently hired superintendent caused a stir during a public Zoom meeting announcing how the they will decide which students get priority seating when in-person learning resumes.“We have to make sure that students, who have been oppressed, that we don’t continue to oppress them, and we give them opportunity,” said school superintendent Dr. Devon Horton of the Evanston/Skokie school district in late July.“We will be targeting our dependent learners – those are students who are marginalized first,” he said.Low-income students, special needs and those dealing with homelessness are just some who will be first in line. There have been angry letters, petitions and even death threats to the superintendent and school board.“Understanding that other folks are experiencing more vulnerability and more harm than my family is experiencing,” says Anya Tanyavutti, a parent of two and the Evanston district’s school board president. “I'm happy to see those resources go to people who need it more.”For the last four years, the Evanston school district has been working on implementing anti-racism resolutions and curricula to address inequity.“Taking an anti-racist stance requires some sort of sacrifice,” says Dr. Onnie Rogers a professor at Northwestern University’s school of Education and Social Policy. “I think that's really the part of racial equity that our country is still getting used to on the ground.”Here in Evanston, the achievement gap does fall along racial lines where Black and Latino students are one-third as likely as white students to meet college readiness benchmarks.The district acknowledges that its plan to allow some students to return before others falls mostly along racial lines. But it is need, they say, not race, that will be the determining factor.“If we simply said we're gonna just reopen for whoever wants to come, then the people who are most well-resourced and most well-connected would likely be able to get those seats prior to people who are challenged with homelessness or challenged with getting food on the table,” says Tanyavutti.And there has been opposition. Arlington, Virginia, based ‘Students for Fair Admissions’- a non-profit advocacy group that has mounted legal challenges to affirmative action, has called the district’s plan unconstitutional.“If that student has unique special needs then that's fine to take those into consideration,” says Edward Blum, president of Students for Fair Admissions. “What is not fine to take into consideration is the skin color or ethnic heritage of students.”“It has been legally reviewed, and I am confident that we are operating within the bounds of our Constitution,” says Tanyavutti.In-person learning is tentatively scheduled to resume in mid-November. And while the district says it will accommodate as many students as possible the priority remains their most vulnerable student population. 2974

The Trump administration says it's ramping up the distribution of rapid coronavirus tests across the US.According to the Department of Health and Human Services, states are on track to receive close to 37 million BinaxNOW antigen tests by the end of the week.The department says the goal is to protect seniors and help states continue to re-open.Officials say they're part of the 150 million BinaxNOW tests that the federal government already planned to deploy nationwide.Abbott says the way it works is that lays the card flat on a countertop, an extraction reagent is added to the card, then the patient gets swabbed from the nose, and then the technician will insert the swab into the test card and fold it over.Abbott Laboratories - which developed the test - says it delivers results in 15 minutes.The HHS points out that more testing does not replace public health guidelines, including wearing masks and washing hands. 933

The Sanderson Sisters are hoping to put a spell on you, 27 years later.Actress Bette Midler was recently on Fox 5 New York's morning show "Good Day New York" where she confirmed that the original cast of "Hocus Pocus" was reuniting for a sequel.“They want to make a movie, they’ve asked us if we were interested and of course all of us said yes,” Midler said in the interview. “I’m game, I’m totally game.”The movie won’t be the first time the Sanderson Sisters would be reuniting. Midler, Sarah Jessica Parker, and Kathy Najimy are coming together, as their “Hocus Pocus” characters, for a special live, one-night-only virtual event, “In Search Of The Sanderson Sisters,” which is set for Friday. 705

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274